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Summary: The effect of prophylactic antifungal drugs on oropharyngeal and anterior nares 
fungal colonization was studied in 20 patients receiving nystatin and 19 patients receiving keto- 
conazole. Surveillance cultures were obtained weekly fora mean of 27.1 f 4 . 8  days in the nystatin 
group and 44.0 f 6.7 days in the ketoconazole group. Initially, 63.2 Yo of nystatin patients and 
77.8 Yo of ketoconazole patients had yeasts in their oropharynx. Neither drug eliminated oropha- 
ryngeal yeast colonization; by the end of the fmt  four weeks of surveillance, 66.7 Yo of the nystatin 
group and 63.6 Yo of the ketoconazole group still had yeasts in the oropharynx. However, both 
drugs caused a reduction in the quantity of yeasts grown on successive cultures. Filamentous 
fungi were isolated in baseline cultures in 42.1 Yo of the nystatin patients and 33.3 9'0 of the ketoco- 
nazole patients. Prophylaxis did not appear to alter carriage of filamentous fungi in the upper air- 
ways. Pathogenic filamentous fungi were only rarely isolated, and this rate did not increase with 
prophylaxis. Resistance to polyene antifungals (nystatin, amphotericin B) or to ketoconazole did 
not occur as a result of prophylaxis. 
Zusammenfassung: Untersuchung iiber die Pilzflora @ Oropharynx und im vorderen Nasen- 
ram unter dem EinfluS einer prophylaktischen antimykotischen Behandlung. 20 Patienten 
erhielten Nystatin und 19 Patienten Ketoconazol. Wiichentliche Kontrollkulturen wurden in der 
Nystatin-Gruppe iiber einen durchschnittlichen Zeitraum von 27,l f 4,8 Tagen und in der Keto- 
conazol-Gruppe iiber 44,O f 6,7 Tage durchgefiihrt. Zu Beginn der Untersuchung hatten 63,2 010 
der Nystatin-Patienten und 77,8 Yo der Ketoconazol-Patienten Hefen im Oropharynx. Keines 
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det beiden Antimykotika eliminierte die oropharyngeale Hefebesiedlung. Nach rlwochiger 
Beobachtung m d e n  Hefen in der Nystath-Gruppe bei 76,7 O/o und in der Ketoconazol-Gruppe 
bei 63,6 O/o im Oropharynx festgestellt. Durch beide Anthnykotika wurde jedoch eine Veninge- 
rung der kulturell nachweisbaren Hefemengen hervorgerufen. Schimmelpilze fanden sich zu 
Beginn der Untersuchung bei 42,l Yo der Nystatin-Patienten und bei 33,3 O/o der Ketoconazol- 
Patienten. Unter der prophylaktischen Behandlung war keine Veningerung des Vorkommens 
derartiger Pilze in den oberen Luftwegen feststellbar. Pathogene Schimmelpilze wurden nur 
sehr selten isoliert und das Vorkommen dieser Pilze stieg unter der prophylaktischen Behand- 
lung nicht an. Erne Resistenz gegeniiber Polyen-Antimykotika (Nystatin, Amphotericin B) oder 
Ketoconazol trat unter der prophylaktischen Behandlung nicht auf. 
Introduction 
Patients with prolonged neutropenia due to cancer chemotherapy are at high risk for deve- 
loping infections with yeast-like fungi, such as Candida (4,16). Overgrowth of yeasts in the 
gastrointestinal tract may cause locally severe infections, such as thrush and esophagitis, and 
may culminate in disseminated infection (20). In an attempt to decrease fungal colonization 
and to prevent serious local yeast infections, as well as disseminated candidiasis, many ten- 
ters routinely use polyene or imidazole antifungal agents prophylactically (3,520).  
Ketoconazole is an imidazole which has been shown to be effective in the treatment of 
chronic mucocutaneous candidiasis (17). It is attractive for use as a prophylactic agent in 
cancer patients because it is easily administered orally and has minimal toxicity. 
This study was undertaken 1) to assess the efficacy of ketoconazole versus nystatin in the 
prevention of infection with yeast-like fungi in neutropenicpatients and 2) to study the effect 
of ketoconazole and nystatin on the fungal flora of the oropharynx and anterior nares. We 
were interested in the possible emergence of potentially pathogenic filamentous fungi or the 
development in yeasts of resistance to antifungal drugs during prophylaxis. A prior report 
documented thoseaspects of the study dealing with the clinical efficacy of ketoconazolever- 
sus nystatin in preventing fungal infections (14); this report details the studies of fungal 
colonization and antifungal drug susceptibility. 
Materials and Methods 
Patients 
Between March 1982 and March 1983, all patients over the age of 16 hospitalized at the 
University of Michigan Hospital with acute leukemia or lymphoma, which was to be treated 
with chemotherapy leading to severe neutropenia, were eligible €or this study. None of the 
patients had received systemic antifungal therapy prior to entering the study. Patients were 
treated in single rooms while hospitalized. Special isolation precautions were not employed, 
and regular hospital food was served. 
Patients were randomized to receive either ketoconazole, 200 mg daily, or nystatin, 
500,000 units, taken as a swish and swallow preparation four times daily. Patients received 
prophylactic treatment throughout the entire period of expected neutropenia (PMN < 500/ 
pl), including outpatient days. 
Fungal surveillance cultures 
Surveillance cultures for fungi were obtained from the oropharynx and anterior nares prior 
to starting prophylaxis and every week thereafter while on the study. The anterior nares were 
sampled with cotton swabs, which were then placed immediately into Stuart’s transport 
medium; cultures ofthe oropharynx were obtained with agargleof 5 ml of sterile 0.9Vosaline. 
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Within an hour of collection, all specimens were inoculated, using the four-quadrant 
method, onto plates containing Sabouraud dextrose agar and Sabouraud dextrose agar with 
chloramphenicol (GIBCO Inc., Grand Island, NY) (13). The plates were incubated at 25OC 
and examined weekly for 4 weeks. The growth of yeasts was graded as rare, few, moderate, or 
abundant by standard criteria (13). The growth offilamentous fungi could not be quantitated 
accurately in this manner and simply was noted as present or absent. 
Identification offngi  
Yeast-like organisms were identified by using the API Clinical Yeast System (Analytab Pro- 
ducts, Inc., Plainview, NY) and germ tube formation (7). Filamentous fungi were identified 
by hyphal and conidial morphology and color using tease-mount preparations, microslide 
cultures, and differential media for Aspergillus (8, 18). 
Antifungal susceptibilily studies 
An agar dilution replicate plate method was used for testing the susceptibility of the isolates 
to ketoconazole, nystatin, and amphotericin B. Ketoconazole powder (Janssen Pharmaceu- 
tica, Inc., New Brunswick, NJ), nystatin powder (Squibb, Inc., Princeton, NJ), and ampho- 
tericin B powder (Squibb, Inc.) were each dissolved in 100 O/o dimethyl sulfoxide (DMSO) 
yielding stock solutions of 1000 pglml. The drugs were further diluted in sterile distilled 
water to give concentrations of 0.06 pg/ml to 500 pg/ml. The final dilutions of the drugs were 
made in molten agar to achieve concentrations of 0.006 pg/ml to 50 pg/ml in the assay plates. 
The agar used for ketoconazole assays was Kimmig agar (E. Merck, Inc., Darmstadt, Federal 
Republic of Germany), adjusted to pH 6.5 (19); the agar used for nystatin and amphotericinB 
studies was antibiotic medium No. 3 in purified agar (Difco, Inc., Detroit, MI). 
Organisms were grown overnight in yeast nitrogen base with dextrose (Difco, Inc.) and 
diluted in 0.9 O/o NaCl to a concentration of 5 x lo4 organisms/ml using a barium standard. 
Plates containing antifungal drugs of varying concentrations were inoculated with a Steers 
replicator which delivered 0.003 ml of each test organism. Therefore, the final inoculum was 
1.5 x lo2 organisms. The plates were incubated 25OC for 48 hours. The minimum inhibitory 
concentration (MIC) was defined as the lowest concentration of drug which prevented 
visible growth on the plates. The MICSO was the concentration of drug which inhibited 50 'Yo 




Forty-three patients were entered into the study. Twenty were randomized to receive ketoco- 
nazole; three of this group were excluded from analysis because of poor compliance 
(2 patients) or transfer to another facility within 7 days of beginning the study (1 patient). 
Twenty-three were randomized to receive nystatin; three were excluded from analysis 
because of poor compliance (1 patient) or death within 7 days of beginning the study 
(2 patients). In addition, 2 patients who failed on nystatin and who were placed on ketocona- 
zole 2 months and 3 months later, respectively, were included in the ketoconazole group as 
well as in the nystatin group. Thus, there were 19 patients in the ketoconazole group and 20 
patients in the nystatin group who were assessed for fungal colonization. 
The mean time over which surveillance cultures were obtained was 27.1 _t 4.8 days for the 
group on nystatin and 44.0 f 6.7 days for the group on ketoconazole. The total number of 
times cultures were obtained was 77 for those on nystatin and 115 for those on ketoconazole. 
The patients given nystatin were followed for a shorter period of time and had fewer cultures 
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Fig. 1 :  The percent of patients 
with oropharyngeal coloniza- 
tion with yeasts before pro- 
phylaxis was begun and during 
the first four weeks of pro- 
phylaxis with ketoconazole or 
nystatin. Numbers above the 
bars refer to the number of 
patients from whom surveil- 
lance cultures were obtained 
KETOCONAZOLE NYSTATIN that week. 
Table 1 
Yeast-like organisms isolated in surveillance cultures from 19 oatients on ketoconazole 
I 
and 20 patients on nystatin 
Organisms Number (oh) isolates 
Ketoconazole Nystatin 
Candida albicans 73 (74.5) 34 (70.8) 
Torulopsis glabrata 2 ( 2.0) 6 (12.5) 
Candida tropicalis 3 ( 3.1) 2 ( 4.2) 
Candida krusei 3 ( 3.1) 4 ( 8.3) 
Candida guilliermondii 0 -  2 ( 4.2) 
Candida species 1 ( 1.0) 0 -  
Total 98 48 
Saccharomyces cerevisiae 1 1  (11.2) 0 -  
Candida parapsilosis 5 ( 5.1) 0 -  
taken due to a higher rate of development of fungal infections (9 infections compared with 3 
in the ketoconazole group), leading to withdrawal of these patients from the study (14). 
Effect ofprophylaxis on yeast-like flora 
The percentage of patients whose baseline cultures yielded yeast-like organisms was similar 
in both groups (Fig. 1). Neither drug eliminated colonization during the first four weeks of 
surveillance (Fig. 1). By the end of four weeks, 66.7 010 of the nystatin group and 63.6 O/o of 
the ketoconazole group had yeasts remaining in their oropharynx. However, of those 
patients who had yeast present in baseline cultures, 66.7 9'0 on nystatin and 57.1 010 on keto- 
conazole showed a fall in the quantity of yeastsgrown on successive cultures. Two patients on 
nystatin and 3 on ketoconazole had abundant yeast growth throughout prophylactic therapy. 
The yeast most commonly isolated was Candida albicans, with all other species occurring 
much less frequently (Tab. 1). Neither drug led to overgrowth by a predominant yeast, such 
as Torulopsis glabrata or C. tropicalis. On only four occasions did anterior nares cultures yield 
yeasts; in all four instances, the growth was very scanty and the organism was present in the 
oropharynx at the same time. 
Effect of prophylaxis on filamentous fungal flora 
The percentage of patients whose baseline cultures yielded filamentous fungi was similar in 
both groups (Fig. 2). Neither drug eliminated carriage of filamentous fungi nor enhanced 
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Filamentous fungi isolated in surveillance cultures from 19 patients on ketoconazole 
and 20 patients on nystatin 
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their growth during the first four weeks of surveillance (Fig. 2). Seventy percent of the posi- 
tive cultures were from the anterior nares in both patient groups. The organisms isolated 
were almost entirely commensal organisms; Aspergillus niger was isolated twice, A. fumiga- 
tus only once, and A. flaws was not found in any culture (Tab. 2). 
Antifungal susceptibility studies 
Comparison of MIC'Oand the MIC9'for each drug showed nodifferences between the yeasts 
isolated in baseline cultures and those isolated during the course of prophylaxis with either 
nystatin or ketoconazole (Tab. 3).  
Discussion 
This study was concerned with finding a prophylactic antifungal regimen which would be 
efficacious in eliminating yeast infections in neutropenicpatients. It was of interest to deter- 
mine if efficacy could be related to decreasing colonization by yeasts in the oropharynx. Also, 
we felt it important to document the consequences of long-term prophylaxis, with regard to 
overgrowth of filamentous fungi, such as Aspergillus, and development of resistance to keto- 
conazole or polyene antifungal agents. 
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The clinical aspects of this study, reported previously, showed that ketoconzole was 
slightly more efficacious than nystatin in preventing serious local yeast infections, such as 
thrush, esophagitis, and vaginitis (14). However, clinical efficacy of ketoconazole was not 
associated with eradication of fungal colonization in the oropharynx. Other studies with 
ketoconazole, as well as those with miconazole or amphotericin B, have shown this dissocia- 
tion between clinical efficacy and effect on colonization (6,10,20). Our study, as well as prior 
ones using other antifungal agents, has shown that the quantity of yeasts in the oropharynx 
does decrease with prophylaxis even though eradication of yeasts does not occur (10,20). 
Overgrowth by strains of yeasts, such as T. glabrata, which may be more resistant to keto- 
conazole, was noted in one preliminary study of ketoconazole prophylaxis in neutropenic 
patients (9). However, our study failed to show emergence of T. glabrata or other resistant 
yeasts. The few patients who were colonized with T. glabrata carried this yeast beforeprophy- 
laxis and demonstrated persistence of the organism in the oropharynx in successive cultures. 
Likewise, another preliminary report noted the emergence of and infection with fila- 
mentous fungi, such as Aspergillus, in patients on ketoconazoleprophylaxis (1). Our patients 
did not show an increase in colonization with filamentous fungi while on prophylaxis. Patho- 
genic Aspergillus species such as A. fumigatus and A. flavus, were rarely isolated in our 
patients. Colonization with pathogenic Aspergillus species is probably most dependent on 
environmental sources (2) and is uncommon in the absence of such a source (15). Previous 
surveillance cultures in neutropenic patients at our institution revealed a seasonal variation 
in colonization with filamentous fungi, with more isolates recovered in the summer months 
(15). 
Prophylactic therapy with ketoconazole or nystatin did not lead to the development of 
ketoconazole-resistant or polyene-resistant yeasts. Polyene resistance has been reported in 
7.4% of isolates from oncology patients at one center (ll), but all isolates were from patients 
who had received systemic amphotericin B, as well as nystatin prophylaxis. Oral nystatin 
alone did not lead to emergence of resistance in our population. The development of resis- 
tance to ketoconazole has been reported only rarely (12). Our study c o n f i i s  that pro- 
phylaxis in neutropenic cancer patients for as long as 4 months is not associated with the 
development of ketoconazole resistant organisms. 
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